A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development

Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 1, 2015, Pages 30-51

  Oda, Shingo ^a   Fukami, Tatsuki ^b   Yokoi, Tsuyoshi ^a   Nakajima, Miki ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Carboxylesterase; Drug development; Drug metabolism; Enzyme induction; Enzyme inhibitors; Gene expression; Substrate; UDP glucuronosyltransferase

Indexed keywords

ARYLACETAMIDE DEACETYLASE; ARYLDIALKYLPHOSPHATASE; CARBOXYLESTERASE; CHOLINESTERASE; CONSTITUTIVE ANDROSTANE RECEPTOR; DIMETHYLANILINE MONOOXYGENASE; ESTERASE; FARNESOID X RECEPTOR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B11; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; DRUG; ISOENZYME;

DNA METHYLATION; DRUG DEVELOPMENT; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; HISTONE MODIFICATION; HUMAN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHARMACOKINETICS; PROCEDURES;

ANIMALS; DRUG DISCOVERY; ESTERASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SUBSTRATE SPECIFICITY;

EID: 84925018693     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2014.12.001     Document Type: Review

References (322)

1. i/AUC) ratios Drug Metab Dispos 32 2004 1201 1208
2. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711 715
3. J. Arrowsmith, and P. Miller Trial watch: phase II and phase III attrition rates 2011-2012 Nat Rev Drug Discov 12 2013 569
4. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, and T. Iyanagi Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet Genomics 15 2005 677 685
5. J.K. Ritter Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions Chem Biol Interact 129 2000 171 193
6. S. Ikushiro, Y. Emi, Y. Kato, S. Yamada, and T. Sakaki Monospecfic antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms Drug Metab Pharmacokinet 21 2006 70 74
7. A.M. Milne, B. Burchell, and M.W.H. Coughtrie A novel method for the Immunoquantification of UDP-glucuronosyltransferases in human tissue Drug Metab Dispos 39 2011 2258 2263
8. S. Oda, M. Nakajima, M. Hatakeyama, T. Fukami, and T. Yokoi Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues Drug Metab Dispos 40 2012 1620 1627
9. C.P. Strassburg, M.P. Manns, and R.H. Tukey Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer Cancer Res 57 1997 2979 2985
10. R.H. Tukey, and C.P. Strassburg Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract Mol Pharmacol 59 2001 405 414
11. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines Drug Metab Dispos 36 2008 1461 1464
12. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, and M. Takamiya Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers Drug Metab Dispos 37 2009 1759 1768
13. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab Dispos 37 2009 32 40
14. M.H. Court, X. Zhang, X. Ding, K.K. Yee, L.M. Hesse, and M. Finel Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues Xenobiotica 42 2012 266 277
15. A. Rowland, J.O. Miners, and P.I. Mackenzie The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification Int J Biochem Cell Biol 45 2013 1121 1132
16. D.E. Harbourt, J.K. Fallon, S. Ito, T. Baba, J.K. Ritter, and G.L. Glish Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry Anal Chem 84 2012 98 105
17. S. Ohtsuki, O. Schaefer, H. Kawakami, T. Inoue, S. Liehner, and A. Saito Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities Drug Metab Dispos 40 2012 83 92
18. O. Schaefer, S. Ohtsuki, H. Kawakami, T. Inoue, S. Liehner, and A. Saito Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes Drug Metab Dispos 40 2012 93 103
19. J.K. Fallon, H. Neubert, T.C. Goosen, and P.C. Smith Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring Drug Metab Dispos 41 2013 2076 2080
20. J.K. Fallon, H. Neubert, R. Hyland, T.C. Goosen, and P.C. Smith Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring J Proteome Res 12 2013 4402 4413
21. Y. Sato, M. Nagata, A. Kawamura, A. Miyashita, and T. Usui Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities Xenobiotica 42 2012 823 829
22. Y. Sato, M. Nagata, K. Tetsuka, K. Tamura, A. Miyashita, and A. Kawamura Optimized methods for targeted peptide-based quantification of human uridine 5′-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry Drug Metab Dispos 42 2014 885 889
23. B. Achour, M.R. Russell, J. Barber, and A. Rostami-Hodjegan Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics Drug Metab Dispos 42 2014 500 510
24. W. Wilson 3rd, F. Pardo-Manuel de Villena, B.D. Lyn-Cook, P.K. Chatterjee, T.A. Bell, and D.A. Detwiler Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15 Genomics 84 2004 707 714
25. D.T. Odom, N. Zizlsperger, D.B. Gordon, G.W. Bell, N.J. Rinaldi, and H.L. Murray Control of pancreas and liver gene expression by HNF transcription factors Science 303 2004 1378 1381
26. P. Bernard, H. Goudonnet, Y. Artur, B. Desvergne, and W. Wahli Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1 Mol Pharmacol 56 1999 526 536
27. D.A. Gardner-Stephen, and P.I. Mackenzie Isolation of the UDP-glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1α Drug Metab Dispos 35 2007 116 120
28. D.J. Auyeung, F.K. Kessler, and J.K. Ritter Differential regulation of alternate UDP-glucuronosyltransferase 1A6 gene promoters by hepatic nuclear factor-1 Toxicol Appl Pharmacol 191 2003 156 166
29. U. Ehmer, S. Kalthoff, T.O. Lankisch, N. Freiberg, M.P. Manns, and C.P. Strassburg Shared regulation of UGT1A7 by hepatocyte nuclear factor (HNF) 1α and HNF4α Drug Metab Dispos 38 2010 1246 1257
30. P.A. Gregory, R.H. Lewinsky, D.A. Gardner-Stephen, and P.I. Mackenzie Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1α and the caudal-related homeodomain protein 2 Mol Pharmacol 65 2004 953 963
31. Y. Ishii, A.J. Hansen, and P.I. Mackenzie Octamer transcription factor-1 enhances hepatic nuclear factor-1α-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter Mol Pharmacol 57 2000 940 947
32. P.A. Gregory, A.J. Hansen, and P.I. Mackenzie Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter Pharmacogenetics 10 2000 809 820
33. F.J. Gonzalez Regulation of hepatocyte nuclear factor 4α-mediated transcription Drug Metab Pharmacokinet 23 2008 2 7
34. P.I. Mackenzie, D.G. Hu, and D.A. Gardner-Stephen The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors Drug Metab Rev 42 2010 95 105
35. O. Barbier, H. Girard, Y. Inoue, H. Duez, L. Villeneuve, and A. Kamiya Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4α Mol Pharmacol 67 2005 241 249
36. D.G. Hu, and P.I. Mackenzie Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells Drug Metab Dispos 38 2010 2105 2109
37. D.G. Hu, D.A. Gardner-Stephen, G. Severi, P.A. Gregory, J. Treloar, and G.G. Giles A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide Mol Pharmacol 78 2010 714 722
38. P.A. Gregory, R.H. Lewinsky, D.A. Gardner-Stephen, and P.I. Mackenzie Regulation of UDP glucuronosyltransferases in the gastrointestinal tract Toxicol Appl Pharmacol 199 2004 354 363
39. P.A. Gregory, D.A. Gardner-Stephen, A. Rogers, M.Z. Michael, and P.I. Mackenzie The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1α cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter Pharmacogenet Genomics 16 2006 527 536
40. S.A. Kliewer, B. Goodwin, and T.M. Willson The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism Endocr Rev 23 2002 687 702
41. J.M. Rae, M.D. Johnson, M.E. Lippman, and D.A. Flockhart Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays J Pharmacol Exp Ther 299 2001 849 857
42. W. Xie, M.F. Yeuh, A. Radominska-Pandya, S.P.S. Saini, Y. Negishi, and B.S. Bottroff Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor Proc Natl Acad Sci U S A 100 2003 4150 4155
43. D. Gardner-stephen, J.M. Heydel, A. Goyal, Y. Lu, W. Xie, and T. Lindblom Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression Drug Metab Dispos 32 2004 340 347
44. S. Mutoh, M. Sobhany, R. Moore, L. Perera, L. Pedersen, and T. Sueyoshi Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling Sci Signal 6 2013 ra31
45. J. Sugatani Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1 Drug Metab Pharmacokinet 28 2013 83 92
46. K.W. Bock, and C. Köhle UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects Methods Enzymol 400 2005 57 75
47. O. Barbier, J. Trottier, J. Kaeding, P. Caron, and M. Verreault Lipid-activated transcription factors control bile acid glucuronidation Mol Cell Biochem 326 2009 3 8
48. J. Trottier, M. Verreault, S. Grepper, D. Monté, J. Bélanger, and J. Kaeding Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver Hepatology 44 2006 1158 1170
49. T.J. Erichsen, A. Aehlen, U. Ehmer, S. Kalthoff, M.P. Manns, and C.P. Strassburg Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids J Hepatol 52 2010 570 578
50. O. Barbier, I.P. Torra, A. Sirvent, T. Claudel, C. Blanquart, and D. Duran-Sandoval FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity Gastroenterology 124 2003 1926 1940
51. J.M. Pascussi, S. Gerbal-Chaloin, C. Duret, M. Daujat-Chavanieu, M.J. Vilarem, and P. Maurel The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences Annu Rev Pharmacol Toxicol 48 2008 1 32
52. O. Barbier, D. Duran-Sandoval, I. Pineda-Torra, V. Kosykh, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme J Biol Chem 278 2003 32852 32860
53. J. Sugatani, K. Yamakawa, E. Tonda, S. Nishitani, K. Yoshinari, and M. Degawa The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics Biochem Pharmacol 67 2004 989 1000
54. T.O. Lankisch, T.C. Gillman, T.J. Erichsen, U. Ehmer, S. Kalthoff, and N. Freiberg Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene Arch Toxicol 82 2008 573 582
55. T.J. Erichsen, U. Ehmer, S. Kalthoff, T.O. Lankisch, T.M. Müller, and P.A. Munzel Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene Toxicol Appl Pharmacol 230 2008 252 260
56. P.A. Münzel, T. Lehmköster, M. Brück, J.K. Ritter, and K.W. Bock Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6 Arch Biochem Biophys 350 1998 72 78
57. S. Kalthoff, U. Ehmer, N. Freiberg, M.P. Manns, and C.P. Strassburg Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltransferase 1A10 J Biol Chem 285 2010 5993 6002
58. I.S. Owens, N.K. Basu, and R. Banerjee UDP-Glucuronosyltransferases: gene structures of UGT1 and UGT2 families Methods Enzymol 400 2005 1 22
59. D. Phelan, G.M. Winter, W.J. Rogers, J.C. Lam, and M.S. Denison Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin Arch Biochem Biophys 357 1998 155 163
60. C.A. Opitz, U.M. Litzenburger, F. Sahm, M. Ott, I. Tritschler, and S. Trump An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 478 2011 197 203
61. Y.D. Wei, L. Bergander, U. Rannug, and A. Rannug Regulation of CYP1A1 transcription via the metabolism of the tryptophan-derived 6-formylindolo[3,2-b]carbazole Arch Biochem Biophys 383 2000 99 107
62. C.R. Chiaro, R.D. Patel, and G.H. Perdew 12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor Mol Pharmacol 74 2008 1649 1656
63. B. Oesch-Bartlomowicz, A. Huelster, O. Wiss, P. Antoniou-Lipfert, C. Dietrich, and M. Arand Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways Proc Natl Acad Sci U S A 102 2005 9218 9223
64. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, and Y. Katoh An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem Biophys Res Commun 236 1997 313 322
65. S. Kalthoff, U. Ehmer, N. Freiberg, M.P. Manns, and C.P. Strassburg Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach Gastroenterology 139 2010 1699 1710
66. M.F. Yueh, and R.H. Tukey Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice J Biol Chem 282 2007 8749 8758
67. P.A. Münzel, S. Schmohl, H. Heel, K. Kälberer, B.S. Bock-Hennig, and K.W. Bock Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in Caco-2 cells Drug Metab Dispos 27 1999 569 573
68. A. Nakamura, M. Nakajima, E. Higashi, H. Yamanaka, and T. Yokoi Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation Pharmacogenet Genomics 18 2008 709 720
69. J. Rey-Campos, T. Chouard, M. Yaniv, and S. Cereghini vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1 EMBO J 10 1991 1445 1457
70. R.S. Illingworth, and A.P. Bird CpG islands - 'A rough guide' FEBS Lett 583 2009 1713 1720
71. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
72. J. Ohgane, S. Yagi, and K. Shiota Epigenetics: the DNA methylation profile of tissue-dependent and differentially methylated regions in cells Placenta 29 2008 S29 S35
73. H. Cedar, and Y. Bergman Linking DNA methylation and histone modification: patterns and paradigms Nat Rev Genet 10 2009 295 304
74. J.F. Gagnon, O. Bernard, L. Villeneuve, B. Têtu, and C. Guillemette Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer Clin Cancer Res 12 2006 1850 1858
75. S. Oda, T. Fukami, T. Yokoi, and M. Nakajima Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney Drug Metab Dispos 41 2013 1738 1743
76. U. Yasar, D.J. Greenblatt, C. Guillemette, and M.H. Court Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers J Pharm Pharmacol 65 2013 874 883
77. S. Oda, T. Fukami, T. Yokoi, and M. Nakajima Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10 Biochem Pharmacol 87 2014 660 667
78. M.B. Fisher, M.F. Paine, T.J. Strelevitz, and S.A. Wrighton The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drugmetabolism Drug Metab Rev 33 2001 273 297
79. R.L. Walsky, J.N. Bauman, K. Bourcier, G. Giddens, K. Lapham, and A. Negahban Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors Drug Metab Dispos 40 2012 1051 1065
80. A. Radominska-Pandya, S.M. Bratton, M.R. Redinbo, and M.J. Miley The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families Drug Metab Rev 42 2010 128 139
81. J. Kim, L. Johannes, B. Goud, C. Antony, C.A. Lingwood, and R. Daneman Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release Proc Natl Acad Sci U S A 95 1998 2997 3002
82. J.H. Chang, P. Yoo, T. Lee, W. Klopf, and D. Takao The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe Mol Pharm 6 2009 1216 1227
83. V. Uchaipichat, L.K. Winner, P.I. Mackenzie, D.J. Elliot, J.A. Williams, and J.O. Miners Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation Br J Clin Pharmacol 61 2006 427 439
84. A. Rowland, D.J. Elliot, J.A. Williams, P.I. Mackenzie, R.G. Dickinson, and J.O. Miners In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction Drug Metab Dispos 34 2006 1055 1062
85. A. Rowland, P. Gaganis, D.J. Elliot, P.I. Mackenzie, K.M. Knights, and J.O. Miners Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation J Pharmacol Exp Ther 321 2007 137 147
86. A. Rowland, K.M. Knights, P.I. Mackenzie, and J.O. Miners The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serumalbumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities Drug Metab Dispos 36 2008 1056 1062
87. P. Raungrut, V. Uchaipichat, D.J. Elliot, B. Janchawee, A.A. Somogyi, and J.O. Miners In vitro-in vivo extrapolation extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans J Pharmacol Exp Ther 334 2010 609 618
88. N. Manevski, J. Troberg, P. Svaluto-Moreolo, K. Dziedzic, J. Yli-Kauhaluoma, and M. Finel Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent PLoS One 8 2013 e54767
89. L. Luukkanen, J. Taskinen, M. Kurkela, R. Kostiainen, J. Hirvonen, and M. Finel Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases Drug Metab Dispos 33 2005 1017 1026
90. R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitoryeffects of UGT substrates Drug Metab Dispos 36 2008 361 367
91. N.K. Basu, M. Kovarova, A. Garza, S. Kubota, T. Saha, and P.S. Mitra Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity Proc Natl Acad Sci U S A 102 2005 6285 6290
92. O. Barbier, C. Girard, R. Breton, A. Bélanger, and D. Hum W.: N-Glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes Biochemistry 39 2000 11540 11552
93. M. Nakajima, T. Koga, H. Sakai, H. Yamanaka, R. Fujiwara, and T. Yokoi N-Glycosylation plays a role in protein folding of human UGT1A9 Biochem Pharmacol 79 2010 1165 1172
94. S. Ikushiro, Y. Emi, and T. Iyanagi Protein-protein interactions between UDP-glucuronosyltransferase isozymes in rat hepatic microsomes Biochemistry 36 1997 7154 7161
95. R. Fujiwara, M. Nakajima, H. Yamanaka, A. Nakamura, M. Katoh, and S. Ikushiro Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms Drug Metab Dispos 35 2007 747 757
96. C.E. Castuma, and R.R. Brenner Effect of fatty acid deficiency on microsomal membrane fluidity and cooperativity of the UDP-glucuronyltransferase Biochim Biophys Acta 729 1983 9 16
97. K. Ito, and J.B. Houston Prediction of human drug clearance from in vitro and preclinical data using physiologically based andempirical approaches Pharm Res 22 2005 103 112
98. M. Mistry, and J.B. Houston Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine Drug Metab Dispos 15 1987 710 717
99. S. Boase, and J.O. Miners In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine Br J Clin Pharmacol 54 2002 493 503
100. M.G. Soars, B. Burchell, and R.J. Riley In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance J Pharmacol Exp Ther 301 2002 382 390
101. J.O. Miners, K.M. Knights, J.B. Houston, and P.I. Mackenzie In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises Biochem Pharmacol 71 2006 1531 1539
102. A. Rowland, K.M. Knights, P.I. Mackenzie, and J.O. Miners Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potentialrole of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters Drug Metab Dispos 37 2009 1395 1403
103. P.J. Kilford, R. Stringer, B. Sohal, J.B. Houston, and A. Galetin Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes Drug Metab Dispos 37 2009 82 89
104. D.C. Kemp, P.W. Fan, and J.C. Stevens Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance Drug Metab Dispos 30 2002 694 700
105. Y. Watanabe, M. Nakajima, and T. Yokoi Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10 Drug Metab Dispos 30 2002 1462 1469
106. J.K. Ritter Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics Expert Opin Drug Metab Toxicol 3 2007 93 107
107. H.E. Cubitt, J.B. Houston, and A. Galetin Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance Pharm Res 26 2009 1073 1083
108. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, and C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1997 1552 1562
109. Z.E. Barter, M.K. Bayliss, P.H. Beaune, A.R. Boobis, D.J. Carlile, and R.J. Edwards Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver Curr Drug Metab 8 2007 33 45
110. Food and Drug Administration (FDA). Guidance for industry guidance for industry drug interaction studies - study design, data analysis.
111. M.H. Court, S. Krishnaswamy, Q. Hao, S.X. Duan, C.J. Patten, and L.L. Von Moltke Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7∗2 polymorphism Drug Metab Dispos 31 2003 1125 1133
112. M. Nishihara, Y. Hiura, N. Kawaguchi, J. Takahashi, and S. Asahi UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by In Vitro analysis and the effect of UGT2B15∗2 mutation Drug Metab Pharmacokinet 28 2013 475 484
113. Z. Cheng, A. Radominska-Pandya, and T.R. Tephly Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10 Drug Metab Dispos 27 1999 1165 1170
114. C.L. Crespi Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research Adv Drug Res 26 1995 179 235
115. K. Rouguieg, N. Picard, F.L. Sauvage, J.M. Gaulier, and P. Marquet Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine andnorbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of humanliver microsomes Drug Metab Dispos 38 2010 40 45
116. L. Zhu, G. Ge, H. Zhang, H. Liu, G. He, and S. Liang Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activityfactor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms Drug Metab Dispos 40 2012 529 538
117. Y. Kato, M. Nakajima, S. Oda, T. Fukami, and T. Yokoi Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitativeestimation of their contribution Drug Metab Dispos 40 2012 240 248
118. C.P. Strassburg, T.O. Lankisch, M.P. Manns, and U. Ehmer Family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability Arch Toxicol 82 2008 415 433
119. D. Zhang, T.J. Chando, D.W. Everett, C.J. Patten, S.S. Dehal, and W.G. Humphreys In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Drug Metab Dispos 33 2005 1729 1739
120. Y. Liu, J. Ramírez, L. House, and M.J. Ratain Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases Drug Metab Dispos 38 2010 32 39
121. W.E. Gall, G. Zawada, B. Mojarrabi, T.R. Tephly, M.D. Green, and B.L. Coffman Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7 J Steroid Biochem Mol Biol 70 1999 101 108
122. B. Mojarrabi, R. Butler, and P.I. Mackenzie cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3 Biochem Biophys Res Commun 225 1996 785 790
123. M.D. Green, C.D. King, B. Mojarrabi, P.I. Mackenzie, and T.R. Tephly Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3 Drug Metab Dispos 26 1998 507 512
124. G.E. Kuehl, J.W. Lampe, J.D. Potter, and J. Bigler Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes Drug Metab Dispos 33 2005 1027 1035
125. T. Prueksaritanont, J.J. Zhao, B. Ma, B.A. Roadcap, C. Tang, and Y. Qiu Mechanistic studies on metabolic interactions between gemfibrozil and statins J Pharmacol Exp Ther 301 2002 1042 1051
126. T. Kubota, B.C. Lewis, D.J. Elliot, P.I. Mackenzie, and J.O. Miners Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4 Mol Pharmacol 72 2007 1054 1062
127. 3 by human UDP-glucuronosyltransferase 1A3 Drug Metab Dispos 33 2005 102 107
128. M.D. Green, W.P. Bishop, and T.R. Tephly Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides Drug Metab Dispos 23 1995 299 302
129. M.D. Green, and T.R. Tephly Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein Drug Metab Dispos 24 1996 356 363
130. D. Zhou, J. Guo, A.J. Linnenbach, C.L. Booth-Genthe, and S.W. Grimm Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine Drug Metab Dispos 38 2010 863 870
131. Y. Kato, T. Izukawa, S. Oda, T. Fukami, M. Finel, and T. Yokoi Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4 Drug Metab Dispos 41 2013 1389 1397
132. V. Uchaipichat, P.I. Mackenzie, D.J. Elliot, and J.O. Miners Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases Drug Metab Dispos 34 2006 449 456
133. T. Ebner, and B. Burchell Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family Drug Metab Dispos 21 1993 50 55
134. N. Hanioka, H. Jinno, T. Tanaka-Kagawa, T. Nishimura, and M. Ando Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection J Pharm Biomed Anal 25 2001 65 75
135. M.H. Court, S.X. Duan, L.L. von Moltke, D.J. Greenblatt, C.J. Patten, and J.O. Miners Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms J Pharmacol Exp Ther 299 2001 998 1006
136. S. Krishnaswamy, S.X. Duan, L.L. Von Moltke, D.J. Greenblatt, and M.H. Court Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6 Drug Metab Dispos 31 2003 133 139
137. K.W. Bock, F.T. Raschko, H. Gschaidmeier, A. Seidel, F. Oesch, and A.D. Grove Mono- and diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7 Biochem Pharmacol 57 1999 653 656
138. C.P. Strassburg, A. Strassburg, N. Nguyen, Q. Li, M.P. Manns, and R.H. Tukey Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus Biochem J 338 1999 489 498
139. M. Ciotti, N. Basu, M. Brangi, and I.S. Owens Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus Biochem Biophys Res Commun 260 1999 199 202
140. N.K. Basu, L. Kole, S. Kubota, and I.S. Owens Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin Drug Metab Dispos 32 2004 768 773
141. C. Guillemette, J.K. Ritter, D.J. Auyeung, F.K. Kessler, and D.E. Housman Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene Pharmacogenetics 10 2000 629 644
142. M.J. Huang, S.S. Yang, M.S. Lin, and C.S. Huang Polymorphisms of uridine-diphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese World J Gastroenterol 11 2005 797 802
143. A. Vogel, S. Kneip, A. Barut, U. Ehmer, R.H. Tukey, and M.P. Manns Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene Gastroenterology 121 2001 1136 1144
144. Y. Wang, N. Kato, Y. Hoshida, M. Otsuka, H. Taniguchi, and M. Moriyama UDP-Glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in Japanese patients with hepatitis C virus infection Clin Cancer Res 10 2004 2441 2446
145. C.S. Tseng, K.S. Tang, H.W. Lo, C.G. Ker, H.C. Teng, and C.S. Huang UDP-Glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age Am J Gastroenterol 100 2005 1758 1763
146. P. Borentain, V. Gérolami, P. Ananian, S. Garcia, A. Noundou, and D. Botta-Fridlund DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients Eur J Cancer 43 2007 2479 2486
147. O. Bernard, and C. Guillemette The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants Drug Metab Dispos 32 2004 775 778
148. L. Ma, J. Sun, Y. Peng, R. Zhang, F. Shao, and X. Hu Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform Drug Metab Dispos 40 2012 734 741
149. C.J. Peer, T.M. Sissung, A. Kim, L. Jain, S. Woo, and E.R. Gardner Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia Clin Cancer Res 18 2012 2099 2107
150. M.H. Court Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases Methods Enzymol 400 2005 104 116
151. J.O. Miners, K. Bowalgaha, D.J. Elliot, P. Baranczewski, and K.M. Knights Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation Drug Metab Dispos 39 2011 644 652
152. D. Dong, and B. Wu In Silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach J Pharm Sci 101 2012 3531 3539
153. R.H. Lewinsky, P.A. Smith, and P.I. Mackenzie Glucuronidation of bioflavonoids by human UGT1A10: structure-function relationships Xenobiotica 35 2005 117 129
154. T. Mizuma Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10 Int J Pharm 378 2009 140 141
155. K. Itäaho, M.H. Court, P. Uutela, R. Kostiainen, A. Radominska-Pandya, and M. Finel Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10 Drug Metab Dispos 37 2009 768 775
156. T. Pillot, M. Ouzzine, S. Fournel-Gigleux, C. Lafaurie, A. Radominska, and B. Burchell Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4 J Biol Chem 268 1993 25636 25642
157. T. Hirohashi, H. Suzuki, H. Takikawa, and Y. Sugiyama ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3) J Biol Chem 275 2000 2905 2910
158. B.L. Coffman, G.R. Rios, C.D. King, and T.R. Tephly Human UGT2B7 catalyzes morphine glucuronidation Drug Metab Dispos 25 1997 1 4
159. S.K. Bae, Y.J. Jeong, C. Lee, and K.H. Liu Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites Xenobiotica 41 2011 437 444
160. Y. Mano, T. Usui, and H. Kamimura The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver Drug Metab Dispos 35 2007 2040 2044
161. D. Turgeon, S. Chouinard, P. Bélanger, S. Picard, J.F. Labbé, and P. Borgeat Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases J Lipid Res 44 2003 1182 1191
162. C.J. Jin, J.O. Miners, K.J. Lillywhite, and P.I. Mackenzie cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily Biochem Biophys Res Commun 194 1993 496 503
163. S. Kaivosaari, P. Toivonen, L.M. Hesse, M. Koskinen, M.H. Court, and M. Finel Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10 Mol Pharmacol 72 2007 761 768
164. C.J. Jin, P.I. Mackenzie, and J.O. Miners The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11 Arch Biochem Biophys 341 1997 207 211
165. M.H. Court, S.X. Duan, C. Guillemette, K. Journault, S. Krishnaswamy, and L.L. Von Moltke Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9 Drug Metab Dispos 30 2002 1257 1265
166. T. Nishiyama, K. Ogura, H. Nakano, T. Ohnuma, T. Kaku, and A. Hiratsuka Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases Biochem Pharmacol 63 2002 1817 1830
167. V. Uchaipichat, C. Suthisisang, and J.O. Miners The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs Drug Metab Dispos 41 2013 1273 1284
168. X. He, L.M. Hesse, S. Hazarika, G. Masse, J.S. Harmatz, and D.J. Greenblatt Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion Br J Clin Pharmacol 68 2009 721 730
169. J.Y. Chung, J.Y. Cho, K.S. Yu, J.R. Kim, H.R. Jung, and K.S. Lim Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers Clin Pharmacol Ther 77 2005 486 494
170. F. Stringer, G. Scott, M. Valbuena, J. Kinley, M. Nishihara, and R. Urquhart The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent Eur J Clin Pharmacol 69 2013 423 430
171. M. Beaulieu, E. Lévesque, D.W. Hum, and A. Bélanger Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids J Biol Chem 271 1996 22855 22862
172. R.M. Balliet, G. Chen, C.J. Gallagher, R.W. Dellinger, D. Sun, and P. Lazarus Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype Cancer Res 69 2009 2981 2989
173. S.P. Kang, J. Ramirez, L. House, W. Zhang, S. Mirkov, and W. Liu A pharmacogenetic study of vorinostat glucuronidation Pharmacogenet Genomics 20 2010 638 641
174. N.S. Wong, E.Z. Seah, L.Z. Wang, W.L. Yeo, H.L. Yap, and B. Chuah Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer Pharmacogenet Genomics 21 2011 760 768
175. UDP Glucuronosyltransferase Homepage: http://www.flinders.edu.au/medicine/sites/clinical-pharmacology/ugt-homepage.cfm.
176. M.K. Shelby, N.J. Cherrington, N.R. Vansell, and C.D. Klaassen Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family Drug Metab Dispos 31 2003 326 333
177. D.B. Buckley, and C.D. Klaassen Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice Drug Metab Dispos 35 2007 121 127
178. M. Nishimura, A. Koeda, H. Morikawa, T. Satoh, S. Narimatsu, and S. Naito Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey Drug Metab Pharmacokinet 24 2009 139 144
179. K.K. Miles, S.T. Stern, P.C. Smith, F.K. Kessler, S. Ali, and J.K. Ritter An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity Drug Metab Dispos 33 2005 1513 1520
180. E. Higashi, A. Ando, S. Iwano, N. Murayama, H. Yamazaki, and Y. Miyamoto Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig Biopharm Drug Dispos 35 2014 313 320
181. M.G. Soars, R.J. Riley, K.A. Findlay, M.J. Coffey, and B. Burchell Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney Drug Metab Dispos 29 2001 121 126
182. K.W. Bock, B.S. Bock-Hennig, P.A. Münzel, J.O. Brandenburg, C.T. Köhle, and M.G. Soars Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by β-naphthoflavone in comparison with humans Biochem Pharmacol 63 2002 1683 1690
183. E.J. Jeong, Y. Liu, H. Lin, and M. Hu Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10 Drug Metab Dispos 33 2005 785 794
184. H. Shiratani, M. Katoh, M. Nakajima, and T. Yokoi Species differences in UDP-glucuronosyltransferase activities in mice and rats Drug Metab Dispos 36 2008 1745 1752
185. N. Hanioka, N. Tanabe, H. Jinno, T. Tanaka-Kagawa, K. Nagaoka, and S. Naito Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes Life Sci 87 2010 261 268
186. Y. Miyake, K. Mayumi, H. Jinno, T. Tanaka-Kagawa, S. Narimatsu, and N. Hanioka cDNA cloning and functional analysis of minipig uridine diphosphate-glucuronosyltransferase 1A1 Biol Pharm Bull 36 2013 452 461
187. J.F. Xiao, X.J. Liu, G.W. Liu, X.Y. Yang, P. Xiao, and X.M. Hou The metabolism of trifluoperazine (TFP) exhibits atypical kinetic behavior in both human liver microsomes (HLMs) and monkey liver microsomes (MyLM) Eur J Drug Metab Pharmacokinet 39 2014 335 337
188. W.N. Aldridge Serum esterase I. Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, propionate and butyrate and a method for their determination Biochem J 53 1953 110 117
189. H.G. Davies, R.J. Richter, M. Keifer, C.A. Broomfield, J. Sowalla, and C.E. Furlong The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin Nat Genet 14 1996 334 336
190. T. Fukami, and T. Yokoi The emerging role of human esterases Drug Metab Pharmacokinet 27 2012 466 477
191. R.S. Holmes, M.W. Wright, S.J. Laulederkind, L.A. Cox, M. Hosokawa, and T. Imai Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins Mamm Genome 21 2010 427 441
192. D.R. Cook, R.L. Stiller, J.N. Weakly, S. Chakravorti, B.W. Brandom, and R.M. Welch In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine Anesth Analg 68 1989 452 456
193. A. Tunek, E. Levin, and L.A. Svensson Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro Biochem Pharmacol 37 1988 3867 3876
194. S. Takusagawa, K. Yajima, A. Miyashita, S. Uehara, T. Iwatsubo, and T. Usui Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist Xenobiotica 42 2012 957 967
195. T. Hioki, T. Fukami, M. Nakajima, and T. Yokoi Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis Drug Metab Dispos 39 2011 1345 1352
196. D.I. Draganov, J.F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B.N. La Du Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities J Lipid Res 46 2005 1239 1247
197. M.R. Probst, P. Jenö, and U.A. Meyer Purification and characterization of a human liver arylacetamide deacetylase Biochem Biophys Res Commun 177 1991 453 459
198. T. Imai Human carboxylesterase isozymes: catalytic properties and rational drug design Drug Metab Pharmacokinet 21 2006 173 185
199. G. Xu, W. Zhang, M.K. Ma, and H.L. McLeod Human carboxylesterase 2 is commonly expressed in tumor tissues and is correlated with activation of irinotecan Clin Cancer Res 8 2002 2605 2611
200. T. Tabata, M. Katoh, S. Tokudome, M. Nakajima, and T. Yokoi Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver Drug Metab Dispos 32 2004 1103 1110
201. Y. Sato, A. Miyashita, T. Iwatsubo, and T. Usui Simultaneous absolute protein quantification of carboxylesterases 1 and 2 in human liver tissue fractions using liquid chromatography-tandem mass spectrometry Drug Metab Dispos 40 2012 1389 1396
202. A. Watanabe, T. Fukami, M. Nakajima, M. Takamiya, Y. Aoki, and T. Yokoi Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis Drug Metab Dispos 37 2009 1513 1520
203. C. Frick, A.G. Atanasov, P. Arnold, J. Ozols, and A. Odermatt Appropriate function of 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase J Biol Chem 279 2004 31131 31138
204. O. Jbilo, C.F. Bartels, A. Chatonnet, J.P. Toutant, and O. Lockridge Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA Toxicon 32 1994 1445 1457
205. A. Perelman, C. Abeijon, C.B. Hirschberg, N.C. Inestrosa, and E. Brandan Differential association and distribution of acetyl- and butyrylcholinesterases within rat liver subcellular organelles J Biol Chem 265 1990 214 220
206. R. Yan, V. Fokina, G.D. Hankins, M.S. Ahmed, and T.N. Nanovskaya The effect of esterases on 17a-hydroxyprogesterone caproate Am J Obstet Gynecol 198 2008 229.e1 229.e5
207. S.T. Reddy, D.J. Wadleigh, V. Grijalva, C. Ng, S. Hama, and A. Gangopadhyay Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids Arterioscler Thromb Vasc Biol 21 2001 542 547
208. J. Ozols Isolation and complete covalent structure of liver microsomal paraoxonase Biochem J 338 1999 265 272
209. Y.S. Huang, L. Woods, and L.G. Sultatos Solubilization and purification of A-esterase from mouse hepatic microsomes Biochem Pharmacol 48 1994 1273 1280
210. C.J. Ng, D.J. Wadleigh, A. Gangopadhyay, S. Hama, V.R. Grijalva, and M. Navab Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein J Biol Chem 48 2001 44444 44449
211. T. Fukami, M. Nakajima, T. Maruichi, S. Takahashi, M. Takamiya, and Y. Aoki Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes Pharmacogenet Genomics 18 2008 911 920
212. M. Hosokawa, T. Furihata, Y. Yaginuma, N. Yamamoto, N. Watanabe, and E. Tsukada Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes Drug Metab Pharmacokinet 23 2008 73 84
213. M. Nishimura, H. Yoshitsugu, S. Naito, and I. Hiraoka Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR YAKUGAKU ZASSHI 122 2002 339 361
214. T. Maruichi, T. Fukami, M. Nakajima, and T. Yokoi Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2) Biochem Pharmacol 79 2010 288 295
215. Y.T. Chen, D. Shi, D. Yang, and B. Yan Antioxidant sulforaphane and sensitizer trinitrobenzene sulfonate induce carboxylesterase-1 through a novel element transactivated by nuclear factor-E2 related factor-2 Biochem Pharmacol 84 2012 864 871
216. T. Hori, and M. Hosokawa DNA methylation and its involvement in carboxylesterase 1A1 (CES1A1) gene expression Xenobiotica 40 2010 119 128
217. M.H. Wu, P. Chen, B.F. Remo, E.H. Cook Jr., S. Das, and M.E. Dolan Characterization of multiple promoters in the human carboxylesterase 2 gene Pharmacogenetics 13 2003 425 435
218. C. Xu, X. Wang, and J.L. Straudinger Regulation of tissue-specific carboxylesterase expression by pregnane X receptor and constitutive androstane receptor Drug Metab Dispos 37 2009 1539 1547
219. Y. Zhang, X. Cheng, L. Aleksunes, and C.D. Klaassen Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice Drug Metab Dispos 40 2012 1191 1197
220. J. Yang, and B. Yan Photochemotherapeutic agent 80methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor Toxicol Sci 95 2007 13 22
221. W. Zhu, L. Song, H. Zhang, L. Matoney, E. Lecluyse, and B. Yan Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats Drug Metab Dispos 28 2000 186 191
222. T. Furihata, M. Hosokawa, A. Fujii, M. Derbel, T. Satoh, and K. Chiba Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma Biochem Pharmacol 69 2005 1287 1297
223. T. Hori, L. Jin, A. Fujii, T. Furihata, Y. Nagahara, and K. Chiba Dexamethasone-mediated transcriptional regulation of rat carboxylesterase 2 gene Xenobiotica 42 2012 614 623
224. A.D. Quiroga, and R. Lehner Role of endoplasmic reticulum neutral lipid hydrolases Trens Endocrinol Metab 22 2011 218 225
225. N.P. Illsley, and C.A. Lamartiniere Endocrine regulation of rat serum cholinesterase activity Endocrinology 108 1981 1737 1743
226. C.A. Lamartiniere Growth hormone modulates serum cholinesterase Endocrinology 118 1986 1252 1254
227. A.R. Durrant, L. Tamayev, and L. Anglister Serum cholinesterases are differentially regulated in normal and dystrophin-deficient mutant mice Front Mol Neurosci 5 2012 73
228. F.R. Sidell, and A. Kaminskis Influence of age, sex, and oral contraceptives on human blood cholinesterase activity Clin Chem 21 1975 1393 1395
229. D.N. Propert, and C.J. Brackenridge The relation of sex, age, smoking status, birth rank and parental ages to pseudocholinesterase activity and phenotypes in a sample of Australian Caucasian adults Hum Genet 32 1976 181 188
230. K.R. Zimmer, C.L. Lencina, A.R. Zimmer, and F.V. Thiesen Influence of physical exercise and gender on acetylcholinesterase and butyrylcholinesterase activity in human blood samples Int J Environ Health Res 22 2012 279 286
231. S. Deakin, I. Leviev, S. Guernier, and R.W. James Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2 Arterioscler Thromb Vasc Biol 23 2003 2083 2089
232. F. Osaki, Y. Ikeda, T. Suehiro, K. Ota, S. Tsuzura, and K. Arii Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells Atherosclerosis 176 2004 279 287
233. V.H. Brophy, R.L. Jampsa, J.B. Clendenning, L.A. McKinstry, G.P. Jarvik, and C.E. Furlong Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression Am J Hum Genet 68 2001 1428 1436
234. C. Gouédard, N. Koum-Besson, R. Barouki, and Y. Morel Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins Mol Pharmacol 63 2003 945 956
235. C. Gouédard, R. Barouki, and Y. Morel Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism Mol Cell Biol 24 2004 5209 5222
236. Y. Kumon, T. Suehiro, Y. Ikeda, and K. Hashimoto Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1β and tumor necrosis factor-α, but is upregulated by interleukin-6 Life Sci 73 2003 2807 2815
237. J. Khateeb, A. Gantman, A.J. Kreitenberg, M. Aviram, and B. Fuhrman Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-γ pathway Atherosclerosis 208 2010 119 125
238. M. Shiner, B. Fuhrman, and M. Aviram Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate phenolic anti-oxidants via PPAR γ and AP-1 pathway activation Atherosclerosis 195 2007 313 321
239. S. Takai, A. Matsuda, Y. Usami, T. Adachi, T. Sugiyama, and Y. Katagiri Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and pI 4.5 from human liver Biol Pharm Bull 20 1997 869 873
240. Z. Sun, D.J. Murry, S.P. Sanghani, W.I. Davis, N.Y. Kedishvili, and Q. Zou Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1 J Pharmacol Exp Ther 310 2004 469 476
241. D. Shi, J. Yang, D. Yang, E.L. LeCluyse, C. Black, and L. You Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by anitplatelet agent clopidogrel J Pharmacol Exp Ther 319 2006 1477 1484
242. M. Tang, M. Mukundan, J. Yang, N. Charpentier, E.L. LeCluyse, and C. Black Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol J Pharmacol Exp Ther 319 2006 1467 1476
243. R. Thomsen, H.B. Rasmussen, K. Linnet, and INDICES Consortium In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors Drug Metab Dispos 42 2014 126 133
244. T. Tabata, M. Katoh, S. Tokudome, M. Hosokawa, K. Chiba, and M. Nakajima Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation Drug Metab Dispos 32 2004 762 767
245. Y. Sato, A. Miyashita, T. Iwatsubo, and T. Usui Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver Drug Metab Dispos 40 2012 902 906
246. R. Humerickhouse, L. Lohrbach, L. Li, W.F. Borson, and M.E. Dolan Characterization of irinotecan hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res 60 2000 1189 1192
247. E.T. Williams, K.O. Jones, G.D. Ponsler, S.M. Lowery, E.J. Perkins, and S.A. Wrighton The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2 Drug Metab Dispos 36 2008 1227 1232
248. E.K. Tarkiainen, J.T. Backman, M. Neuvonen, P. Neuvonen, M. Schwab, and M. Niemi Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans Clin Pharmacol Ther 92 2012 68 71
249. H.J. Zhu, D.I. Appel, J.A. Johnson, K.D. Chavin, and J.S. Markowitz Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril Biochem Pharmacol 77 2009 1266 1272
250. H.J. Zhu, and J.S. Markowitz Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants Drug Metab Dispos 37 2009 264 267
251. A. Watanabe, T. Fukami, S. Takahashi, Y. Kobayashi, N. Nakagawa, and M. Nakajima Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen Drug Metab Dispos 38 2010 1532 1537
252. A. Nakajima, T. Fukami, Y. Kobayashi, A. Watanabe, M. Nakajima, and T. Yokoi Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine Biochem Pharmacol 82 2011 1747 1756
253. M. Shimizu, T. Fukami, Y. Ito, T. Kurokawa, M. Kariya, and M. Nakajima Indiplon is hydrolyzed by arylacetamide deacetylase in human liver Drug Metab Dispos 42 2014 751 758
254. A. Madan, A. Fisher, L. Jin, D. Chapman, and H.P. Bozigian In vitro metabolism of indiplon and an assessment of its drug interaction potential Xenobiotica 37 2007 736 752
255. M. Ohbuchi, M. Miyata, D. Nagai, M. Shimada, K. Yoshinari, and Y. Yamazoe Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity Drug Metab Dispos 37 2009 97 105
256. Y. Kobayashi, T. Fukami, R. Higuchi, M. Nakajima, and T. Yokoi Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia Biochem Pharmacol 84 2012 1196 1206
257. M. Shimizu, T. Fukami, Y. Kobayashi, M. Takamiya, Y. Aoki, and M. Nakajima A novel polymorphic allele of human arylacetamide deacetylase leads to diminished enzyme activity Drug Metab Dispos 40 2012 1183 1190
258. F. Pérez Guillermo, C.M. Martinez Pretel, F. Tarín Royo, M.J. Peña Macias, J.A. Alvarez Ossorio, and C.J. Vidal Prolonged suxamethonium-induced neuromuscular blockade associated with organophosphate poisoning Br J Anaesth 61 1988 233 236
259. D. Ostergaard, F.S. Jensen, E. Jensen, L.T. Skovgaard, and J. Viby-Mogensen Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase Acta Anaesthesiol Scand 37 1993 314 318
260. A. Vaisi-Raygani, Z. Rahimi, H. Kharazi, H. Tavilani, M. Aminiani, and A. Kiani Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran Clin Biochem 40 2007 629 633
261. C.L. Morton, r. M. Wadkins, M.K. Danks, and P.M. Potter The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase Cancer Res 59 1999 1458 1463
262. D.J. Stewart, T. Inaba, B.K. Tang, and W. Kalow hydrolysis of cocaine in human plasma by cholinesterase Life Sci 20 1977 1557 1564
263. M.J. Hatfield, L. Tsurkan, J.L. Hyatt, X. Yu, C.C. Edwards, and L.D. Hicks Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin Br J Pharmacol 160 2010 1916 1928
264. K. Tougou, A. Nakamura, S. Watanabe, Y. Okuyama, and A. Morino Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antifloxacin agent Drug Metab Dispos 26 1998 355 359
265. T. Ishizuka, I. Fujimori, A. Nishida, H. Sakurai, Y. Yoshigae, and K. Nakahara Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism Drug Metab Dispos 40 2012 374 380
266. S. Billecke, D. Draganov, R. Counsell, P. Stetson, C. Watson, and C. Hsu Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters Drug Metab Dispos 28 2000 1335 1342
267. T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, and J.H. Lin Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab Metab 30 2002 505 512
268. H. Fujino, I. Yamada, S. Shimada, M. Yoneda, and J. Kojima Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization Xenobiotica 33 2003 27 41
269. M. Shimizu, T. Fukami, M. Nakajima, and T. Yokoi Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase Drug Metab Dispos 42 2014 1103 1109
270. F.G. Bahar, K. Ohura, T. Ogihara, and T. Imai Species difference of esterase expression and hydrolase activity in plasma J Pharm Sci 101 2012 3979 3988
271. Y. Miao, N. He, and J.J. Zhu History and new developments of assays for cholinesterase activity and inhibition Chem Rev 110 2010 5216 5234
272. L.G. Tsurkan, M.J. Hatfield, C.C. Edwards, J.L. Hyatt, and P.M. Potter Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors Chem Biol Interact 203 2013 226 230
273. C.L. Kuo, and B.N. La, Du Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity Drug Metab Dispos 26 1998 653 660
274. S.K. Quinney, S.P. Sanghani, W.I. Davis, T.D. Hurley, Z. Sun, and D.J. Murry Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide J Pharmacol Exp Ther 313 2005 1011 1016
275. X. Yanjiao, Z. Chengliang, L. Xiping, W. Tao, R. Xiuhua, and L. Dong Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro Drug Metab Pharmacokinet 28 2013 468 474
276. R.M. Wadkins, J.L. Hyatt, X. Wei, K.J. Yoon, M. Wierdl, and C.C. Edwards Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases J Med Chem 48 2005 2906 2915
277. E.I. Parkinson, M. Jason Hatfield, L. Tsurkan, J.L. Hyatt, C.C. Edwards, and L.D. Hicks Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones Bioorg Med Chem 19 2011 4635 4643
278. J.W. Chang, D.K. Nomura, and B.F. Cravatt A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis Chem Biol 18 2011 476 484
279. H. Okazaki, M. Igarashi, M. Nishi, M. Sekiya, M. Tajima, and S. Takase Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages J Biol Chem 283 2008 33357 33364
280. T. Fukami, S. Takahashi, N. Nakagawa, T. Maruichi, M. Nakajima, and T. Yokoi In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities Drug Metab Dispos 38 2010 2173 2178
281. S.P. Sanghani, W.I. Davis, N.G. Dumaual, A. Mahrenholz, and W.F. Bosron Identification of microsomal rat liver carboxylesterases and their activity with retinyl palmitate Eur J Biochem 269 2002 4387 4398
282. K. Ohura, K. Tasaka, M. Hashimoto, and T. Imai Distinct patterns of aging effects on the expression and activity of carboxylestarses in rat liver and intestine Drug Metab Dispos 42 2014 264 273
283. S. Takahashi, M. Katoh, T. Saitoh, M. Nakajima, and T. Yokoi Different inhibitory effects in rat and human carboxylesterases Drug Metab Dispos 37 2009 956 961
284. R.D. Jones, A.M. Taylor, E.Y. Tong, and J.J. Repa Carboxylesterases are uniquely expressed among tissues and regulated by nuclear hormone receptors in the mouse Drug Metab Dispos 41 2013 40 49
285. B. Li, M. Sediacek, I. Manoharan, R. Boopathy, E.G. Duysen, and P. Masson Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma Biochem Pharmacol 70 2005 1673 1684
286. C.L. Morton, L. Iacono, J.L. Hyatt, K.R. Taylor, P.J. Cheshire, and P.J. Houghton Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice Cancer Chemother Pharmacol 56 2005 629 636
287. E.G. Duysen, F. Koentgen, G.R. Williams, C.M. Timperley, L.M. Schopfer, and D.M. Cerasoli Production of ES1 plasma carboxylesterase knockout mice for toxicity studies Chem Res Toxicol 24 2011 1891 1898
288. M. Taketani, M. Shii, K. Ohura, S. Ninomiya, and T. Imai Carboxylesterase in the liver and small intestine of experimental animals and human Life Sci 81 2007 924 932
289. M. Inoue, M. Morikawa, M. Tsuboi, and M. Sugiura Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs Jpn J Pharmacol 29 1979 9 16
290. M. Hosokawa, T. Maki, and T. Satoh Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans Arch Biochem Biophys 277 1990 219 227
291. L. Luan, T. Sugiyama, S. Takai, Y. Usami, T. Adachi, and Y. Katagiri Purification and characterization of pranlukast hydrolase from rat liver microsomes: the hydrolase is identical to carboxylesterase pI 6.2 Biol Pharm Bull 20 1997 71 75
292. Y.H. Park, and S.S. Lee Identification and characterization of capsaicin-hydrolyzing enzymes purified from rat liver microsomes Biochem Mol Biol Int 34 1994 351 360
293. Y. Kobayashi, T. Fukami, A. Nakajima, A. Watanabe, M. Nakajima, and T. Yokoi Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse Drug Metab Dispos 40 2012 671 679
294. L.T. Tenconi, and E. Beretta Urinary and biliary metabolites of rifampicin in different animal species Proc Eur Soc Drug Toxit 11 1970 80 85
295. K. Chan A simultaneous determination of rifampin and 25-deacetylrifampicin in cerebrospinal fluid and plasma of rabbit by liquid chromatography Zhongguo Yao Li Xue Bao 8 1987 555 559
296. G. Binda, E. Domenichini, A. Gottardi, B. Orlandi, E. Ortelli, and B. Pacini Rifampicin, a general review Arzneimittel-Forsch 21 1971 1907 1977
297. N.F. Smith, W.D. Figg, and A. Spareboom Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 2006 163 175
298. E. Araki, M. Ishikawa, M. Iigo, T. Koide, M. Itabashi, and A. Hoshi Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11 Jpn J Cancer Res 84 1993 697 702
299. R. Goda, D. Nagai, Y. Akiyama, K. Nishikawa, I. Ikemoto, and Y. Aizawa Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients Drug Metab Dispos 34 2006 828 835
300. T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J.H. Lin Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos 30 2002 1280 1287
301. N. Fujiyama, M. Miura, S. Kato, T. Sone, M. Isobe, and S. Satoh Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil Drug Metab Dispos 38 2010 2210 2217
302. N. Picard, D. Ratanasavanh, A. Prémaud, Y. Le Meur, and P. Marquet Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 2005 139 146
303. S. Riedmaier, K. Klein, U. Hofmann, J.E. Keskitalo, P.J. Neuvonen, and M. Schwab UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin Pharmacol Ther 87 2010 65 73
304. H. Spahn-Langguth, and L.Z. Benet Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24 1992 5 47
305. P.C. Smith, A.F. McDonagh, and L.Z. Benet Irreversible binding of zomepirac to plasma protein in vitro and in vivo J Clin Invest 77 1986 934 939
306. A.M. Williams, S. Worrall, J. de Jersey, and R.G. Dickinson Studies on the reactivity of acyl glucuronides - III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans Biochem Pharmacol 43 1992 745 755
307. R.G. Dickinson, P.V. baker, and A.R. King Studies on the reactivity of acyl glucuronides - VII. Salicyl acyl glucuronide reactivity in vitro and covalent binding of salicylic acid to plasma protein of humans tasking aspirin Biochem Pharmacol 47 1994 469 476
308. A. Ding, P. Zia-Amirhosseini, A.F. McDonagh, A.L. Burlingame, and L.Z. Benet Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry Drug Metab Dispos 23 1995 369 376
309. B.C. Sallustio, Y.C. Decraaf, J.S. Weekley, and P.C. Burcham Bioactivation of carboxylic acid compounds by UDP-glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity Chem Res Toxicol 19 2006 683 691
310. H.T. Southwood, Y.C. DeGraaf, P.I. Mackenzie, J.O. Miners, P.C. Burcham, and B.C. Sallustio Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways Chem Res Toxicol 20 2007 1520 1527
311. T. Koga, R. Fujiwara, M. Nakajima, and T. Yokoi Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes Drug Metab Dispos 39 2011 54 60
312. E. Wieland, M. Shipkova, U. Schellhaas, E. Schütz, P.D. Niedmann, and V.W. Armstrong Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33 2000 107 113
313. T. Miyashita, K. Kimura, T. Fukami, M. Nakajima, and T. Yokoi Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs Drug Metab Dispos 42 2014 1 8
314. R. Sawamura, N. Okudaira, K. Watanabe, T. Murai, Y. Kobayashi, and M. Tachibana Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide Drug Metab Dispos 38 2010 1857 1864
315. N. Jinno, S. Ohashi, M. Tagashira, T. Kohira, and S. Yamada A simple method to evaluate reactivity of acylglucuronides optimized for early stage drug discovery Biol Pharm Bull 36 2013 1509 1513
316. C. Volland, H. Sun, J. Dammeyer, and L.Z. Benet Stereoselective degradation of the fenoprofen acyl glucuronide enatiomers and irreversible binding to plasma protein Drug Metab Dispos 19 1991 1080 1086
317. P.C. Smith, W.Q. Song, and R.J. Rodriguez Covalent binding of etodolac acyl glucuronide to albumin in vitro Drug Metab Dispos 20 1992 962 965
318. N. Dubois-Presle, F. Lapicque, M. Maurice, S. Fournel-Gigleux, J. Magdalou, and M. Abiteboul Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide Mol Pharmacol 47 1995 647 653
319. B.C. Sallustio, B.A. Fairchild, and P.R. Pannall Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-β-d-glucuronide Drug Metab Dispos 25 1997 55 60
320. E. Suzuki, N. Yamamura, Y. Ogura, D. Nakai, K. Kubota, and N. Kobayashi Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics Drug Metab Dispos 38 2010 1538 1544
321. A. Iwamura, T. Fukami, R. Higuchi, M. Nakajima, and T. Yokoi Human a/b hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver J Biol Chem 287 2012 9240 9249
322. Y. Ito, T. Fukami, T. Yokoi, and M. Nakajima An orphanesterase ABHD10 modulates probenecid acyl glucuronidation in human liver Drug Metab Dispos 42 2014 2109 2116